Get the Stockscreener App
45.35
4.23%
1.84
Pre-market:
45.39
0.04
+0.09%
Scholar Rock Holding Corp stock is traded at $45.35, with a volume of 1.09M.
It is up +4.23% in the last 24 hours and up +61.68% over the past month.
Scholar Rock Holding Corp is a late-stage biopharmaceutical company focused on discovering, developing, and delivering innovative medicines for treating serious diseases in which signaling by protein growth factors plays a fundamental role. Its pipeline includes Neuromuscular and Obesity, Immuno-oncology, Fibrotic Disease, and Hematology. The group operates and manages its business as a single segment to assess performance and make operating decisions.
See More
Previous Close:
$43.51
Open:
$43.01
24h Volume:
1.09M
Relative Volume:
0.42
Market Cap:
$4.63B
Revenue:
$47.30M
Net Income/Loss:
$-225.97M
P/E Ratio:
-19.30
EPS:
-2.35
Net Cash Flow:
$-188.86M
1W Performance:
+5.10%
1M Performance:
+61.68%
6M Performance:
+47.14%
1Y Performance:
+14.03%
1-Day Range:
$42.83
$45.47
1-Week Range:
$39.51
$45.47
52-Week Range:
$22.71
$46.98
Scholar Rock Holding Corp Stock (SRRK) Company Profile
Name
Scholar Rock Holding Corp
Sector
Industry
Phone
857-259-3860
Address
301 BINNEY STREET, CAMBRIDGE, MA
Compare SRRK with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SRRK
Scholar Rock Holding Corp
|
45.35 | 4.44B | 47.30M | -225.97M | -188.86M | -2.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
457.26 | 117.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
722.83 | 76.06B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.56 | 62.53B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
916.31 | 56.75B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
205.04 | 44.10B | 447.02M | -1.18B | -906.14M | -6.1812 |
Scholar Rock Holding Corp Stock (SRRK) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-18-25 | Initiated | Wolfe Research | Outperform |
| Oct-09-25 | Initiated | BofA Securities | Buy |
| Sep-17-25 | Initiated | Barclays | Overweight |
| Sep-15-25 | Initiated | Leerink Partners | Outperform |
| Aug-21-25 | Resumed | Jefferies | Buy |
| Jul-30-25 | Resumed | Raymond James | Strong Buy |
| Jul-17-25 | Initiated | Cantor Fitzgerald | Overweight |
| Nov-26-24 | Reiterated | H.C. Wainwright | Buy |
| Oct-07-24 | Reiterated | H.C. Wainwright | Buy |
| Mar-28-24 | Initiated | Raymond James | Strong Buy |
| Oct-25-23 | Upgrade | Jefferies | Hold → Buy |
| Apr-03-23 | Resumed | Piper Sandler | Overweight |
| Sep-19-22 | Resumed | H.C. Wainwright | Buy |
| Jul-12-22 | Initiated | Truist | Buy |
| Mar-23-22 | Initiated | H.C. Wainwright | Buy |
| Dec-22-21 | Downgrade | Jefferies | Buy → Hold |
| Nov-19-21 | Initiated | Piper Sandler | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Jan-11-21 | Initiated | Credit Suisse | Outperform |
| Jan-06-21 | Initiated | JP Morgan | Overweight |
| Mar-12-20 | Initiated | Robert W. Baird | Outperform |
View All
Scholar Rock Holding Corp Stock (SRRK) Latest News
Scholar Rock (SRRK) Valuation Revisited After FDA Warning Letter to Key Manufacturing Partner - simplywall.st
Scholar Rock (SRRK) valuation after FDA manufacturing update and apitegromab resubmission plans - Yahoo Finance
Scholar Rock (NASDAQ:SRRK) Trading Up 7.8%Still a Buy? - MarketBeat
Scholar Rock Holding Corporation $SRRK Position Cut by Fisher Asset Management LLC - MarketBeat
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away - AOL.com
Scholar Rock (NASDAQ:SRRK) Shares Gap DownShould You Sell? - MarketBeat
Scholar Rock Stock Is Still Down 40% From 2021 Highs — And One Investor Just Walked Away - The Motley Fool
FDA Manufacturing Letter And Backup Plant Plans Could Be A Game Changer For Scholar Rock (SRRK) - simplywall.st
Can Scholar Rock Holding Corporation stock deliver strong Q4 earningsWeekly Market Outlook & Low Risk High Win Rate Stock Picks - Newser
Scholar Rock updates on Catalent Indiana FDA warning letter and apitegromab timeline - Investing.com Nigeria
Scholar Rock Updates on FDA Warning and Apitegromab Launch Plans - TradingView
Scholar Rock Holding (SRRK) Stock Analysis Report | Financials & Insights - Benzinga
Truist Financial Maintains Scholar Rock(SRRK.US) With Buy Rating - 富途牛牛
Inceptionr LLC Invests $205,000 in Scholar Rock Holding Corporation $SRRK - MarketBeat
Loomis Sayles & Co. L P Sells 17,706 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation $SRRK Shares Bought by American Century Companies Inc. - MarketBeat
Aisling Capital Management LP's Scholar Rock Holding Corp(SRRK) Holding History - GuruFocus
Universal Beteiligungs und Servicegesellschaft mbH Grows Holdings in Scholar Rock Holding Corporation $SRRK - MarketBeat
Intech Investment Management LLC Lowers Stock Holdings in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding Corporation $SRRK Shares Bought by Geode Capital Management LLC - MarketBeat
Scholar Rock Holding (SRRK): A Fresh Look at Valuation Following Recent Biotech Sector Moves - sahmcapital.com
Ensign Peak Advisors Inc Purchases 264,693 Shares of Scholar Rock Holding Corporation $SRRK - MarketBeat
After tax other income/expense of Scholar Rock Holding Corp. – HAM:2QK - TradingView
Scholar Rock (NASDAQ:SRRK) Stock Rating Upgraded by Wolfe Research - MarketBeat
Eagle Health Investments LP Makes New $9.54 Million Investment in Scholar Rock Holding Corporation $SRRK - MarketBeat
Scholar Rock Holding CorporationCommon Stock (NQ: SRRK - Markets Financial Content
Cantor Fitzgerald Lowers Earnings Estimates for Scholar Rock - MarketBeat
Will Scholar Rock Holding Corporation (2QK) stock maintain strong growthJuly 2025 Trends & Stepwise Trade Signal Implementation - newser.com
Why Scholar Rock Holding Corporation (2QK) stock appears on watchlistsTrade Risk Summary & Short-Term High Return Ideas - newser.com
Using data filters to optimize entry into Scholar Rock Holding CorporationPortfolio Risk Report & Smart Swing Trading Alerts - newser.com
Using economic indicators to assess Scholar Rock Holding Corporation potential2025 Volatility Report & Smart Money Movement Alerts - newser.com
Will Scholar Rock Holding Corporation (2QK) stock attract long term capital inflowsJuly 2025 Spike Watch & Technical Pattern Based Buy Signals - newser.com
JPMorgan Chase & Co. Boosts Scholar Rock (NASDAQ:SRRK) Price Target to $47.00 - MarketBeat
Scholar Rock (NASDAQ:SRRK) Shares Up 4.6% Following Analyst Upgrade - MarketBeat
Scholar Rock (NASDAQ:SRRK) Earns Outperform Rating from Analysts at Wolfe Research - MarketBeat
Published on: 2025-11-19 06:08:10 - newser.com
Wolfe Research Initiates Coverage of Scholar Rock Holding (SRRK) with Outperform Recommendation - Nasdaq
Scholar Rock Holding buy JPMorgan Chase & Co. - sharewise.com
Scholar Rock at Jefferies: Navigating FDA Challenges By Investing.com - Investing.com India
Scholar Rock at Jefferies: Navigating FDA Challenges - Investing.com
Scholar Rock Holding (SRRK): Wolfe Research Initiates Coverage w - GuruFocus
SRRK: JP Morgan Raises Price Target to $47, Maintains Overweight Rating | SRRK Stock News - GuruFocus
Scholar Rock (NASDAQ:SRRK) Price Target Raised to $45.00 - MarketBeat
J.P. Morgan Maintains Scholar Rock(SRRK.US) With Buy Rating, Raises Target Price to $47 - 富途牛牛
Sun Life and Kansas City Royals Raise $50K for Boys & Girls Clubs of Greater KC - Stock Titan
Scholar Rock Holding Corporation stock trend forecastTrade Entry Report & Weekly Setup with ROI Potential - newser.com
Scholar Rock Holding Corporation (NASDAQ:SRRK) Given Consensus Recommendation of "Buy" by Brokerages - MarketBeat
Wall Street Analysts Are Bullish on Top Healthcare Picks - The Globe and Mail
Wolfe Research initiates Scholar Rock stock with Outperform rating By Investing.com - Investing.com Nigeria
Barclays Maintains Scholar Rock Holding (SRRK) Overweight Recommendation - Nasdaq
Wolfe Research initiates Scholar Rock stock with Outperform rating - Investing.com
Scholar Rock Holding Corp Stock (SRRK) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.10%
1.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):